
SWITZERLAND – HBM BioVentures to apply for a listing on the SWX
Venture capital company HBM BioVentures Ltd plans to expand its shareholder base through an IPO. The company intends to issue a limited number of new shares and list all shares on the SWX Swiss Exchange shortly. HBM BioVentures invests globally in emerging companies in the biotechnology and medical technology sectors. The investment focus is emerging private and small-cap public companies that are at varying stages of development. The portfolio includes private companies (59%), public companies originating from the private portfolio (17%), other public companies (11%) and other current assets (13%, including cash of 8%) at this time. It is well diversified in terms of geography, therapeutic areas, the portfolio companies' stage of development and the timing of investments.
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater